Drugs / Merimepodib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00088504 | Jul 2004 → Oct 2006 | chronic hepatitis C virus infection | Vertex Pharmaceuticals Incorporated | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04410354 Comparator | Jun → Dec 2020 | COVID-19 | ViralClear Pharmaceuticals, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2004-05-04 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV vrtx.com ↗
All combinations of merimepodib (MMPD) and VX-950 resulted in greater reduction of HCV RNA than either agent alone, and computational analysis determined that the antiviral effects of MMPD and VX-950 were additive to moderately synergistic. |
| 2004-04-16 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches vrtx.com ↗
results for patients enrolled in the extension phase of a pilot Phase IIa study designed to evaluate the safety and tolerability of merimepodib |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2004-05-04 | Vertex Pharmaceuticals Incorporated | Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV vrtx.com ↗ |
| 2004-04-16 | Vertex Pharmaceuticals Incorporated | Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches vrtx.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Merimepodib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00088504 ↗ |
| Known as | MMPD | “The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with...” NCT04410354 ↗1“Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC)” PMID 19852040 ↗ Dec 2009 |
| Known as | VI-21,497 | ChEMBL registry synonym — accepted as the source's own label CHEMBL304087 ↗ |
| Known as | VX-497 | ChEMBL registry synonym — accepted as the source's own label CHEMBL304087 ↗ |
| Action | Inhibit | “Inosine-5'-monophosphate dehydrogenase 1 inhibitor” CHEMBL304087 ↗1“inosine monophosphate dehydrogenase inhibitor” PMID 19852040 ↗ Dec 2009 |
| Modality | Small molecule | — CHEMBL304087 ↗ |
| Route | Oral | “orally administered” PMID 19852040 ↗ Dec 2009 |
| Target | IMPDH1 | “Inosine-5'-monophosphate dehydrogenase 1 inhibitor” CHEMBL304087 ↗ |